Shares of Edgewise Therapeutics (EWTX) soared 30% in the pre-market trading on Thursday after it reported positive top-line data of EDG-7500 from an early-stage study in healthy subjects and Part A (single-dose arm) of a mid-stage study in patients with obstructive hypertrophic cardiomyopathy (HCM). EWTX's EDG-7500 Shows Superior Efficacy in Both Studies Per the data readout from the phase I study in healthy adults, no meaningful changes in left ventricle ejection fraction (LVEF), an important predictor of ...